ePIPAC

Peritoneal metastases (PM) is cancer that has spread to the peritoneum, which is the membrane that lines the abdominal cavity, from other organs. Globally, a patient is diagnosed with PM every 30 seconds. It is common in advanced gynaecological and gastrointestinal cancer with ~170,000 new cases per annum in EU alone. Despite recent developments in advanced therapeutics such as CAR-T treatment, cytoreductive surgery and intraperitoneal chemotherapy, PM is still fatal and patients with PM demonstrate worse clinical outcomes than those with liver and lung metastases. Pressurised intra-peritoneal aerosolised chemotherapy (PIPAC) is a new minimally invasive, localised chemotherapy delivery method for the treatment of PM, whereby chemotherapy is introduced directly into the abdomen. However, PIPAC has significant shortcomings that are limiting its uptake, namely poor drug distribution, suboptimal tumour penetration, prolonged drug sedimentation times. Alesi is seeking to optimise its proprietary surgical electrostatic precipitation technology to PIPAC. This will improve distribution and tissue uptake of the crucial chemotherapy drugs, reduce overall procedure time and avoid dangerous contamination of surgical tools and surfaces in the operating room.